Form 4: Apellis General Counsel Sells Shares Under 10b5-1 Plan

Apellis Pharmaceuticals' General Counsel, David O. Watson, sold 5,000 shares of common stock at $24.49 per share as part of a pre-arranged 10b5-1 trading plan.

Summary

• David O. Watson, General Counsel of Apellis Pharmaceuticals, Inc. (APLS), reported a sale of common stock.
• The transaction involved the disposition of 5,000 shares of Apellis common stock.
• The shares were sold at a price of $24.49 per share.
• The sale occurred on December 16, 2025.
• This transaction was executed pursuant to a Rule 10b5-1 trading plan established on March 3, 2025.
• Following the transaction, Mr. Watson directly beneficially owns 103,730 shares of common stock.
• Additionally, Mr. Watson indirectly beneficially owns 10,000 shares through a custodial account for minor children and 50,136 shares through The David O. Watson Irrevocable Trust of 2023.

Sentiment

Score: 6

Explanation: The transaction is a pre-scheduled sale under a 10b5-1 plan, which is generally considered a neutral event as it does not imply a change in the insider's view of the company's prospects. It's a routine personal financial management action.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on new, non-public information.

Negatives

• An insider sale, even if pre-planned, reduces the insider's direct equity stake in the company.

Risks

• While a 10b5-1 plan mitigates concerns, significant or frequent insider selling could be perceived by some investors as a lack of confidence, potentially impacting investor sentiment.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This insider transaction is a routine disclosure for publicly traded companies and does not inherently reflect broader industry trends or competitive positioning. Such sales are common for executives managing personal finances or diversifying portfolios.

Comparison to Industry Standards

• Insider sales executed under Rule 10b5-1 plans are a standard practice for corporate executives to manage their equity holdings in a compliant manner, avoiding accusations of trading on material non-public information. This transaction aligns with typical corporate governance practices for managing executive compensation and personal financial planning.

Related Party Transactions

• David O. Watson indirectly beneficially owns 10,000 shares through a custodial account for his minor children.
• David O. Watson indirectly beneficially owns 50,136 shares through The David O. Watson Irrevocable Trust of 2023, for which William Zorn is the trustee. Mr. Watson disclaims beneficial ownership over these shares except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in direct insider ownership, but its pre-planned nature under a 10b5-1 plan typically minimizes negative sentiment.
• Employees, Customers, Suppliers, Creditors: No direct impact is indicated by this routine insider transaction.

Next Steps

• The filing does not mention any specific future actions, events, or milestones for the company or the reporting person beyond the reported transaction.

Key Dates

Recommendation

This Form 4 reports a routine, pre-scheduled sale of shares by an insider under a 10b5-1 plan. Such transactions are typically for personal financial management and do not reflect a change in the company's fundamental outlook or performance. Therefore, it does not provide a basis for a 'buy' or 'sell' recommendation, and a 'hold' stance is appropriate as it offers no new material information to alter an investment thesis.

Keywords

Apellis Pharmaceuticals, APLS, Insider Trading, Form 4, Stock Sale, David O. Watson, General Counsel, 10b5-1 Plan, Equity Transaction, Beneficial Ownership